JN.1 is a descendant of the Omicron lineage, was first detected in September in the US...
Digital Desk: In a recent development, UK health authorities have identified new symptoms associated with the latest Covid-19 sub-variant, JN.1. Previously, symptoms were mostly limited to upper respiratory tract infections, but recent data from December 2023 by the UK's Office for National Statistics (ONS) revealed two new symptoms: trouble sleeping and anxiety.
Over 10% of individuals with COVID-19 in the UK consistently reported anxiety or excess worrying since early November, as indicated by the ONS winter Covid report.
The most common symptoms now include runny nose, cough, headache, fatigue, muscle pain, sore throat, trouble sleeping, and anxiety.
Notably, the once-common symptoms of loss of taste and smell are currently reported in only 2 to 3% of UK cases. These findings coincide with a global increase in Covid-19 infections, with the WHO reporting a 52% rise in new cases over the past month.
In India, where there were 573 fresh cases and two deaths in the last 24 hours, a total of 197 cases of JN.1 have been reported in 11 states. The majority of JN.1 cases exhibit mild symptoms, with severity seen in less than 10% of cases, particularly in individuals with pre-existing health conditions. The overall fatality rate is less than 2%, and deaths are infrequent, with most patients recovering at home.
JN.1, a descendant of the Omicron lineage, was first detected in September in the US and has spread to over 40 countries. It has been classified as a variant of interest (VOI) by the WHO.
Derived from BA.2.86, also known as Pirola, JN.1 carries an additional L455S mutation in the spike protein, increasing its transmissibility.
Health experts emphasize the importance of preventive measures such as wearing masks, frequent handwashing, and avoiding public gatherings to curb the spread of the virus. Stay informed and vigilant to protect yourself and others in the face of evolving Covid-19 variants.
Leave A Comment